Related Experiment Video
Updated: Jul 16, 2026
09:44
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Melanoma imaging with pretargeted bivalent bacteriophage
Jessica R Newton1, Yubin Miao, Susan L Deutscher
1Department of Biochemistry, University of Missouri, Columbia, Missouri, USA.
Summary
This study demonstrates a novel two-step pretargeting-imaging system using multivalent bifunctional phage displaying melanocortin-1 receptor-homing peptides for enhanced in vivo cancer imaging.
Area of Science:
- Biotechnology
- Molecular Imaging
- Oncology
Background:
- Bacteriophage (phage) display is used for selecting tissue-binding clones.
- Synthetic peptides often have lower affinity than phage due to lack of avidity.
- Multivalent phage displaying targeting peptides can improve in vivo imaging.
Purpose of the Study:
- To develop and validate a phage-based pretargeting-imaging system for cancer.
- To utilize multivalent phage displaying melanocortin-1 receptor (MC1R)-homing peptides for melanoma imaging.
Main Methods:
- Generated and biotinylated phage displaying multiple alpha-melanocyte-stimulating hormone (alpha-MSH) peptide analogs.
- Conjugated streptavidin to diethylenetriaminepentaacetic acid for radiolabeling with Indium-111 ((111)In).
- Evaluated phage specificity and tumor targeting in vitro and in vivo using murine melanoma models.
Main Results:
- MSH2.0 phage showed specific binding to B16-F1 melanoma in vitro and in vivo.
- In vivo studies demonstrated significant melanoma uptake of radiolabeled streptavidin after phage injection.
- SPECT/CT imaging confirmed retention of phage within melanoma tumors.
Conclusions:
- Multivalent bifunctional phage can be effectively used in a two-step pretargeting-imaging system.
- This approach enhances the specificity and sensitivity of in vivo cancer imaging.
- Phage display technology offers a promising platform for developing targeted molecular imaging agents.
